
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte is fundamentally attractive because OPUS-1 delivered a near-clean sweep for VAX-31, with all 20 shared serotypes versus PCV20 meeting the stringent non-inferiority bar and 17 of 19 versus PCV21, while also showing a safety profile similar to both comparators. That result materially de-risks the adult program, supports broad label potential from launch, and strengthens the company’s competitive position in an $8B+ pneumococcal market where coverage breadth matters for payers and physicians. The outlook is further supported by a deep pipeline and upcoming catalysts, including pediatric data expected by the end of 1H27, VAX-A1 phase 1 data in 2H27, and a BLA submission targeted for the first half of 2028.
Bears say
Vaxcyte is facing a pressured fundamental setup because challenging market conditions and the near-term catalyst path imply limited visibility until potentially eight months to value-inflecting pediatric phase 2 data, while the shares are also exposed to typical financing pressure. Its vaccine pipeline remains highly uncertain, as VAX-31 and other candidates must prove safety, efficacy, and meaningful differentiation against approved, well-established pneumococcal vaccines and competitors with greater resources. Financially, profitability is not expected for several years, additional capital may be required, and development, regulatory, manufacturing, commercial, and patent risks could all impair long-term value creation.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Vaxcyte (PCVX) Forecast
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares